Elmar Burchardt to Speak at Stem Cell Summit (Apr 23-25, 2014 - Cambridge, MA)
Elmar Burchardt, VP of Regenerative Medicine at Pfizer, to Keynote Present at Stem Cell Summit (Apr 23-25, 2014 in Cambridge, MA)
CAMBRIDGE, MA, January 28, 2014 /24-7PressRelease/ -- Elmar Burchardt, Vice President of Regenerative Medicine at Pfizer, will give a Keynote Presentation at the Stem Cell Summit 2014 to be held on April 23-25, 2014 in Cambridge, MA.
With over 17 years of experience in the areas of cell therapy, hematology and cardiovascular diseases, Dr. Burchardt has designed and conducted international clinical trials from Phases I through IV, including hematopoietic stem cell transplantation and studies in hematology, immunology, oncology, bone regeneration and in cardiovascular diseases.
In its 11th year, the Stem Cell Summit 2014 includes two parallel conferences including joint sessions. This summit provides cutting-edge information on developments in all areas of stem cell research including the biology, medicine, applications, regulations, and commercialization of stem cells.
Conference A: Stem Cell Research & Regenerative Medicine:
Advances in Adult & Pluripotent Stem Cells
New Paradigms in Cell Therapy
Cells for Drug Discovery & Diagnostics
Conference B: Stem Cell Commercialization & Partnering:
Novel Technologies in Stem Cell Research
Overcoming Challenges in Clinical Development
Commercialization: Bringing Therapeutics to Market
Panel Discussion: Strategic Partnering
Joint Sessions: (Conference A+B)
Applications of Regulatory guidance in Advancing Cell Therapy
For more information, please visit http://www.gtcbio.com/stemcellsummit
GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic institutions, government organizations and the financial community.
GTC (Global Technology Community), LLC, is a privately held company founded in 2002.
Disclaimer: If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7PressRelease. We are unable to assist you with any information regarding this release. 24-7PressRelease disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.